Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Weilin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9432-2649; OpenAlex author ID A5100357261. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 1, last author 17)
Trials
1
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 5 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper, 1 trial · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 28

  1. A Chemotherapy Progression Decision Score for Treatment Selection After Initial Assessment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70903↗
  2. Spatiotemporally controlled ferritin-targeting PROTAC nanoplatform for visualized manipulation of endogenous "Iron pool" in pancreatic cancer therapy. Co-author DOI 10.1016/j.mtbio.2025.102661↗
  3. Identification of pyroptosis-related lncRNAs for constructing a prognostic model and their correlation with immune infiltration in pancreatic cancer. Last author DOI 10.1016/j.hbpd.2024.09.004↗
  4. The Moonlighting Function of Glutaminase 2 Promotes Immune Evasion of Pancreatic Ductal Adenocarcinoma by Tubulin Tyrosine Ligase-like 1-Mediated Yes1 Associat… Co-author DOI 10.1053/j.gastro.2025.01.240↗
  5. The Regulatory Role of Brown Adipocyte - Related Gene CALU in the Progression, Immune Microenvironment and Treatment Response of Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-6709366/v1↗
  6. Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress. Last author DOI 10.3389/fonc.2024.1414456↗
  7. Single-cell transcriptome reveals the heterogeneity of malignant ductal cells and the prognostic value of REG4 and SPINK1 in primary pancreatic ductal adenocar… Last author DOI 10.7717/peerj.17350↗
  8. The application of radiofrequency ablation in pancreatic cancer liver-only recurrence after radical pancreatectomy. Last author DOI 10.1007/s12032-023-02065-y↗
  9. USPs in Pancreatic Ductal Adenocarcinoma: A Comprehensive Bioinformatic Analysis of Expression, Prognostic Significance, and Immune Infiltration. Last author DOI 10.1155/2022/6109052↗
  10. ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis. Last author DOI 10.3389/fmolb.2021.764900↗
  11. The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. Last author DOI 10.3389/fonc.2021.640863↗
  12. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. Last author DOI 10.1002/cam4.2764↗
  13. Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle. Last author DOI 10.3389/fonc.2020.00049↗
  14. Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xeno… Last author DOI 10.1016/j.canlet.2019.08.019↗
  15. GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells. Last author DOI 10.3892/etm.2019.7845↗
  16. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Co-author DOI 10.1021/acs.molpharmaceut.8b00298↗
  17. miR‑448 targets Rab2B and is pivotal in the suppression of pancreatic cancer. Last author DOI 10.3892/or.2018.6562↗
  18. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Co-author DOI 10.1016/j.biomaterials.2017.08.002↗
  19. HINT2 triggers mitochondrial Ca2+ influx by regulating the mitochondrial Ca2+ uniporter (MCU) complex and enhances gemcitabine apoptotic effect in pancreatic c… Last author DOI 10.1016/j.canlet.2017.09.020↗
  20. Inhibitor of Pancreatic Cancer by RHIL1RA-Letter. Last author DOI 10.1158/1078-0432.ccr-16-3270↗
  21. Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer. Co-author DOI 10.18632/oncotarget.14642↗
  22. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation in… Last author DOI 10.3892/etm.2017.4740↗
  23. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analys… Last author DOI 10.1038/srep36944↗
  24. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  25. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Co-author DOI 10.1016/s1499-3872(15)60400-3↗
  26. Overexpression of β3 Chains of Laminin-332 is Associated With Clinicopathologic Features and Decreased Survival in Patients With Pancreatic Adenocarcinoma. First author DOI 10.1097/pai.0000000000000115↗
  27. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  28. Bioinformatics method to predict two regulation mechanism: TF-miRNA-mRNA and lncRNA-miRNA-mRNA in pancreatic cancer. Co-author DOI 10.1007/s12013-014-0142-y↗

Trials 1

  1. Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers Study chair NCT06139042↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dongkai Zhou · 7 shared papers, 2015–2024 · strength 0.82
  2. Mugahed Abdullah Hasan Albahde · 4 shared papers, 2019–2024 · strength 0.61
  3. Yuan Ding · 4 shared papers, 2019–2026 · strength 0.61
  4. Hao Xu · 4 shared papers, 2019–2024 · strength 0.54
  5. Shusen Zheng · 6 shared papers, 2015–2017 · strength 0.40
  6. Yutian Ji · 1 shared paper, 2024 · strength 0.36
  7. Yining Wang · 1 shared paper, 2026 · strength 0.30
  8. Xiaoyan Yang · 1 shared paper, 2026 · strength 0.30
  9. Ri‐Sheng Yu · 1 shared paper, 2026 · strength 0.30
  10. Ye Zhou · 1 shared paper, 2025 · strength 0.28
  11. Linshi Zhang · 3 shared papers, 2019–2020 · strength 0.28
  12. Jiarong Zhou · 3 shared papers, 2019–2020 · strength 0.28
  13. Fang Wu · 1 shared paper, 2025 · strength 0.27
  14. Xufan Cai · 1 shared paper, 2025 · strength 0.27
  15. Chengfang Wang · 1 shared paper, 2023 · strength 0.26
  16. Yixin Zhang · 1 shared paper, 2026 · strength 0.24
  17. Gaopeng Li · 1 shared paper, 2026 · strength 0.24
  18. Daqian Xu · 1 shared paper, 2026 · strength 0.24
  19. Jieer Ying · 1 shared paper, 2026 · strength 0.24
  20. Yuan Ding · 1 shared paper, 2025 · strength 0.22
  21. Haotian Fu · 1 shared paper, 2025 · strength 0.22
  22. Xiao Chen · 1 shared paper, 2025 · strength 0.22
  23. Yizhi Wang · 1 shared paper, 2022 · strength 0.19
  24. Huilin Zheng · 2 shared papers, 2019–2020 · strength 0.19
  25. Sinan Lu · 2 shared papers, 2016–2017 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.